Cite
HARVARD Citation
Austin, D. et al. (2023). Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data. CPT: pharmacometrics & systems pharmacology. pp. 87-94. [Online].